Lipoprotein (a) is an independent predictor of cardiovascular events in Mediterranean women (Progetto Atena)

Abstract

Get full access to this article

View all access options for this article.

References

Mehta

Beckie

DeVon

, et al. Acute myocardial infarction in women: a scientific statement from the American Heart Association. Circulation 2016; 133: 916–947.

Panico

Dello Iacovo

Celentano

, et al. Progetto ATENA, a study on the etiology of major chronic diseases in women: design, rationale and objectives. Eur J Epidemiol 1992; 8: 601–608.

Gentile

Iannuzzo

Mattiello

, et al. Association between Lp (a) and atherosclerosis in menopausal women without metabolic syndrome. Biomark Med 2016; 10: 397–402.

Gentile

Iannuzzo

Mattiello

, et al. Association between Lp (a) and small dense LDL in menopausal women without metabolic syndrome. Clin Biochem Nutr 2017; 61: 130–134.

Paré

Çaku

McQueen

, et al. INTERHEART Investigators. Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups. Circulation 2019; 139: 1472–1482.

Nordestgaard

Chapman

Ray

, et al. European Atherosclerosis Society Consensus Panel. Lipoprotein (a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31: 2844–2853.

Verbeek

Boekholdt

Stoekenbroek

, et al. Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study. J Lipid Res 2016; 57: 697–705.

Cook

Mora

Ridker

. Lipoprotein (a) and cardiovascular risk prediction among women. J Am Coll Cardiol 2018; 72: 287–296.

Ruscica

Watts

Sirtori

. PCSK9 monoclonal antibodies and lipoprotein apheresis for lowering lipoprotein(a): making choices in an era of RNA-based therapies. Eur J Prev Cardiol 2019; 26: 998–1000.

10.

Sbrana

Dal Pino

Bigazzi

, et al. Effect of proprotein convertase subtilisin/kexin type 9 inhibitors on lipoprotein(a) still to be unravelled. Eur J Prev Cardiol 2019; 26: 782–782.